1-21. (Canceled)
22. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element that includes a light emitting layer comprising an electroluminescent organic compound and a metal complex,
wherein the metal complex comprises a lattice structure in which metal atoms and ligands are alternately arranged, and
the ligands are located in lattice points and the lattice points are cross-linked through the ligands in the lattice structure.
23. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element that includes a light emitting layer comprising an electroluminescent organic compound and a metal complex,
wherein the metal complex comprises a lattice structure in which metal atoms and ligands are alternately arranged, and
the metal atoms are located in lattice points and the lattice points are cross-linked through the metal atoms in the lattice structure.
24. The mobile telephone according to claim 22 wherein the metal atoms have atomic numbers equal to or larger than rubidium.
25. The mobile telephone according to claim 23 wherein the metal atoms have atomic numbers equal to or larger than rubidium.
26. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a lattice structure in which sites with the dinuclear structure and ligands are alternately arranged, and
the sites with the dinuclear structure are located in lattice points and the lattice points are cross-linked through the ligands in the lattice structure.
27. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a lattice structure in which sites with the dinuclear structure and ligands are alternately arranged, and
the ligands are located in lattice points and the lattice points are cross-linked through the sites with the dinuclear structure in the lattice structure.
28. The mobile telephone according to claim 26, wherein each of the metal atoms is one element selected from the group 5 to 11 elements of the periodic table.
29. The mobile telephone according to claim 27 wherein each of the metal atoms is one element selected from the group 5 to 11 elements of the periodic table.
30. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a divalent metal ion of one element selected from the group 5 to 11 elements of the period table and a ligand comprising a dicarboxylic ion.
31. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a divalent metal ion of one element selected from the group 5 to 11 elements of the period table and a ligand represented by the general formula,
where a denotes one selected from the group consisting of a substituent comprising a paraphenylene group, a substituent comprising a heterocyclic ring, and a substituent comprising a condensed ring.
32. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a divalent metal ion of one element selected from the group 5 to 11 elements of the periodic table and a ligand represented by the general formula,
where b denotes at least one cycloalkylene group and the b may comprise a substituent.
33. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a divalent metal ion of one element selected from the group 5 to 11 elements of the periodic table and a ligand represented by the general formula,
where n denotes an integer equal to or larger than 1.
34. A mobile telephone comprising a main body and a display portion attached to the main body, said display portion including a light emitting device comprising:
an organic EL element having a light emitting layer that includes an electroluminescent organic compound and a metal complex with a dinuclear structure comprising two metal atoms as nuclei,
wherein the metal complex comprises a divalent metal ion of one element selected from the group 5 to 11 elements of the periodic table and a ligand represented by the general formula,
where c denotes one selected from the group consisting of a substituent comprising an aryl group, a substituent comprising a heterocyclic ring, and a substituent comprising a condensed ring.
35. The mobile telephone according to claim 22 further comprising an anode and a cathode, wherein said light emitting layer is interposed between said anode and said cathode.
36. The mobile telephone according to claim 26 further comprising an anode and a cathode, wherein said light emitting layer is interposed between said anode and said cathode.
37. The mobile telephone according to claim 30 further comprising an anode and a cathode, wherein said light emitting layer is interposed between said anode and said cathode.
38. The mobile telephone according to claim 31 further comprising an anode and a cathode, wherein said light emitting layer is interposed between said anode and said cathode.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-28. (canceled)
29. An isolated polynucleotide that encodes a polypeptide comprising SEQ ID NO:16 or a truncated portion thereof of at least 50 amino acid residues wherein said portion retains the ability to enhance ubiquitination of phoshorylated IB.
30. An antisense polynucleotide comprising at least 10 consecutive nucleotides complementary to a polynucleotide according to claim 29.
31. An expression vector comprising a polynucleotide according to claim 29.
32. A host cell transformed or transfected with an expression vector according to claim 31.
33. A pharmaceutical composition comprising:
a) an isolated human E3 ubiquitin ligase polypeptide, said E3 ubiquitin ligase polypeptide comprising SEQ ID NO:16 or a truncated portion thereof of at least 50 amino acid residues wherein said portion retains the ability to enhance ubiquitination of phoshorylated IB, such that the polypeptide enhances ubiquitination of phoshorylated IB; and
b) a physiologically acceptable carrier.
34. An isolated antibody, or antigen binding fragment thereof that binds to a human E3 ubiquitin ligase sequence recited in SEQ ID NO:16.
35. An antibody or fragment thereof according to claim 34, wherein the antibody is a monoclonal antibody.
36. A pharmaceutical composition comprising an antibody or fragment thereof according to claim 34, in combination with a physiologically acceptable carrier.
37. A method for modulating NF-B activity in a patient comprising administering to a patient a pharmaceutical composition according to claim 33, wherein said pharmaceutical composition is in an amount sufficient to modulate NF-B activity in the patient.
38. A method according to claim 16, wherein the disorder is selected from the group consisting of inflammatory diseases, autoimmune diseases, cancer and viral infection.
39. A method for screening for an agent that modulates NF-B activity comprising the steps of:
a) contacting a candidate agent with an isolated human E3 ubiquitin ligase polypeptide comprising a variant of SEQ ID NO:16 that differs therefrom at no more than 10% of the amino acid residues of SEQ ID NO:16 wherein said variant retains the ability to ubiquitination of phosphorylated IB, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent; and
b) determining whether the polypeptide enhances ubiquitination of phoshorylated IB, relative to a predetermined ability of the polypeptide to enhance ubiquitination of phoshorylated IB in the absence of the candidate agent, and, if so;
c) identifying an agent that modulates NF-B activity.
40. A method according to claim 39, wherein the candidate agent is a small molecule.
41. A method for screening for an agent that modulates NF-B activity comprising the steps of:
a) contacting a candidate agent with an isolated human E3 ubiquitin ligase polypeptide comprising a variant of SEQ ID NO:16 that differs therefrom at no more than 10% of the amino acid residues od SEQ ID NO:16 wherein said variant retains the ability to enhance ubiquitination of phoshorylated IB, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent;
b) determining whether the polypeptide enhances ubiquitination of phosphorylated IB, relative to a predetermined ability of the polypeptide to enhance ubiquitination of phosphorylated IB in the absence of the candidate agent, and, if so;
c) identifying an agent that modulates NF-B activity.
42. A method for screening for an agent that modulates NF-B activity comprising the steps of:
a) contacting a candidate agent with an isolated human E3 ubiquitin ligase polypeptide comprising SEQ ID NO:16 or a truncated portion thereof of at least 50 amino acid residues wherein said portion retains the ability to enhance ubiquitination of phoshorylated IB, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent;
b) determining whether the polypeptide binds phosphorylated IB or a phosphorylated IB peptide comprising SEQ ID NO:8 or SEQ ID NO:9, and if so;
c) identifying an agent that modulates NF-B activity.
43. A method for screening for an agent that modulates NF-B activity comprising the steps of:
a) contacting a candidate agent with an isolated human E3 ubiquitin ligase polypeptide comprising SEQ ID NO:16 or a truncated portion thereof of at least 50 amino acid residues wherein said portion retains the ability to enhance ubiquitination of phoshorylated IB, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent;
b) determining whether the polypeptide modulates the release of NF-B from IB or the nuclear translocation of NF-B, and if so;
c) identifying an agent that modulates NF-B activity.